Memantine for NMDA Receptor Modulation in Neuropsychiatric Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuropsychiatric disorders associated with aberrant NMDA receptor activity, such as systemic lupus erythematosus and neuropsychiatric systemic lupus erythematosus, have limited efficacy in addressing neuropsychiatric manifestations.
Innovation Solution
Administering a therapeutically effective amount of memantine or its pharmaceutically acceptable salt to subjects with mutations in the GRIN2A gene, autoantibodies to ionotropic glutamate receptor NMDA 2A, or anti-double-stranded DNA antibodies that cross-react with NMDA receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies (NSAIDs, antimalarials, corticosteroids, immunosuppressants, biologics) are used to treat SLE, then systemic inflammation is controlled, but neuropsychiatric manifestations remain ineffective
Solution Approach 1:
The patent applies parameter changes by introducing memantine, a compound with specific pharmacological properties (NMDA receptor antagonism) that differs fundamentally from conventional SLE therapies. This changes the therapeutic parameter from general immunosuppression to targeted NMDA receptor modulation, thereby improving efficacy for neuropsychiatric manifestations while maintaining adaptability through mechanism-based treatment
2Object-affected harmful factors
If anti-NR2 antibodies are present at high concentrations, then they are pathogenic promoting excitotoxicity, but conventional therapies do not effectively address this mechanism
Solution Approach 1:
The patent converts the harmful effect of anti-NR2 antibodies (excitotoxicity) into a treatable condition by using memantine, an NMDA receptor antagonist. The drug blocks the pathological overactivation of NMDA receptors caused by high concentrations of anti-NR2 antibodies, thereby converting the harmful excitotoxic mechanism into a controlled therapeutic target that can be effectively managed
Solution Approach 2:
The patent applies preliminary anti-action by administering memantine to preemptively block NMDA receptor overactivation before excitotoxic damage occurs. This preventive approach counteracts the pathogenic effect of anti-NR2 antibodies by establishing protective NMDA receptor blockade in advance, preventing the harmful cascade of excitotoxicity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Memantine effectively treats neuropsychiatric disorders by blocking excessive NMDA receptor activity, reducing excitotoxicity, and alleviating symptoms like cognitive impairment and psychosis, offering a more targeted approach than existing therapies.
Implementation Method 1
Memantine is a competitive antagonist at the phencyclidine site of the N-methyl-D-aspartate (NMDA) receptor
Implementation Method 2
at high concentrations anti-NR2 antibodies are pathogenic as they promote excitotoxicity through enhanced mitochondrial permeability transition
Data Source
AI summary
The present disclosure is directed to methods for treating a neuropsychiatric disorder associated with expression of autoantibodies to ionotropic glutamate receptor, NMD A 2A (GiuN2A), expression of anti-double-stranded (ds) DNA antibodies that cross react with one or more subunits of the NMD A receptor, or a mutation in the ionotropic glutamate receptor NMD A type subunit 2A (GRIN2A) gene. The methods involve administering a memantine, or a pharmaceutically acceptable salt thereof, to a subject suffering from a neuropsychiatric disorder associated with expression of GluN2A or a mutation in the GRIN2A gene.